Quest Diagnostics (DGX)
(Real Time Quote from BATS)
$139.71 USD
+5.45 (4.06%)
Updated Apr 29, 2024 03:14 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DGX 139.71 +5.45(4.06%)
Will DGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Other News for DGX
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
Quest Diagnostics, LabCorp climb following FDA testing oversight rule
Quest Diagnostics Foundation and Green Bronx Machine Expand Collaboration to Bring Acclaimed Indoor Gardening Curriculum to More Communities and Raise Awareness for Impact of Nutrition Education on Health Equity
Labcorp price target lowered by $21 at Barclays, here's why